25 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
Management and Oversight
Shareholder Dialogue with the Company
Code of Business Conduct and Ethics
Corporate Governance Documents
Compensation … industry and operations will result in efficient and competent oversight of our various core competencies.
Qualified candidates will be considered
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
of the periods presented herein.
Remediation
The Company's management, under the oversight of the Audit Committee, is committed to further strengthen … , disgorgement, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
Management and Oversight
Shareholder Dialogue with the Company
Code of Business Conduct and Ethics
Corporate Governance Documents
Compensation Committee … and competent oversight of our various core competencies.
Qualified candidates will be considered without regard to race, color, religion, sex
424B3
NAMS
NewAmsterdam Pharma Company NV
12 Mar 24
Prospectus supplement
4:18pm
and has the ability to make decisions with respect to the voting and disposition of the Ordinary Shares subject to the oversight of the board of trustees
POS AM
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
to the oversight of the board of trustees (or similar entity) of Janus Henderson Biotech. Under the terms of its management contract with Janus Henderson
10-K
crs4ei8
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
f40lb0n xjntbk5l
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
F-3
EX-1.2
3jxee
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
4m075qg
15 Aug 23
Prospectus supplement
4:52pm
POS AM
2qmph1gcz z9h
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
yd88yzm cewgpxb6uju
7 Aug 23
Research and development expenses
7:24am
424B3
lzd68zh5fz4qh
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-1.1
fodikqv
9 Jun 23
Current report (foreign)
9:39pm
424B3
krtwk6 oh68
8 Jun 23
Prospectus supplement
5:01pm
424B3
lmt33bk9ofrlrc2yf
6 Jun 23
Prospectus supplement
4:20pm
424B3
2fwsh
25 Apr 23
Prospectus supplement
8:14am
POS AM
vfcq68q mjfw9edbb8g
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
y500oe cp0
19 Dec 22
Registration statement (foreign)
6:22pm
6-K
EX-2.1
xgig6
23 Nov 22
Current report (foreign)
4:36pm